

Liječenje skvamozne neoplazije površine oka: prikaz slučaja

Merlak, Maja; Bilen Babić, Marijana; Dekanić, Andrea

Source / Izvornik: **Medicina Fluminensis : Medicina Fluminensis, 2017, 53, 236 - 240**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

https://doi.org/10.21860/medflum2017_179758

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:273734>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-12-02**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



Treatment of ocular surface squamous neoplasia: Case report

Liječenje skvamozne neoplazije površine oka: prikaz slučaja

Maja Merlak¹, Marijana Bilen Babić^{1*}, Andrea Dekanić²

¹Department of Ophthalmology, Clinical Hospital Center Rijeka, Rijeka

²Department of Pathology and Pathological Anatomy, Clinical Hospital Center Rijeka, Rijeka

Abstract. Aim: Ocular surface squamous neoplasia (OSSN) is a term that encompasses a wide and varied spectrum of very rare dysplastic disease of cornea and conjunctiva, ranging from conjunctival intraepithelial neoplasia (CIN), carcinoma in situ (CIS) to invasive squamous cell carcinoma (SCC) of conjunctiva and/or cornea. **Case report:** In our case report, we present squamous cell carcinoma of the conjunctiva and cornea in a 78-year old man. Our diagnostic algorithm included: slit lamp and fundus examination, gonioscopy, impression cytology (IC) and magnetic resonance imaging (MRI). The patient underwent surgical excisional biopsy of the lesion and intraoperative cryotherapy of the cut conjunctival edges and sclera-conjunctiva base region. Following surgical therapy, we started topical 0.02 % (0.2 mg/ml) Mitomycin C (MMC) application daily for 14 days. Control excisional biopsy of conjunctival edge and abrasion of involved cornea were performed following the last day of topical chemotherapy. Our control excisional biopsy revealed tumor positive corneal tissue and the second cycle of topical 0.04 % (0.4 mg/ml) MMC chemotherapy was started for next 3 weeks. The patient has been followed-up for 20 months through monthly-based visits, with no recurrence of the disease. **Conclusions:** OSSN is a surgical challenge requiring a specialized 'no-touch' (NT) technique. In our case, the combination of surgical excision with intraoperative cryotherapy and topical chemotherapy with 0.02 % MMC application for 14 days, completed with second cycle of topical 0.04 % MMC drops for the next 21 days given the positive control biopsy, proved to be a good choice for eradication of OSSN with accurate further monitoring of the patient.

Key words: conjunctiva; cornea; eye neoplasms; mitomycin; squamous cell neoplasms

Sažetak. Cilj: Skvamozna neoplazija površine oka (OSSN) vrlo je rijetka displastična bolest rožnice i spojnice oka, sa slikom u rasponu od konjunktivalne intraepitelne neoplazije (CIN), karcinoma *in situ* (CIS) do invazivnog skvamocelularnog konjunktive i/ili rožnice (SCC). **Prikaz slučaja:** Opisali smo slučaj invazivnog skvamocelularnog karcinoma konjunktive i rožnice kod 78-godišnjeg pacijenta. Dijagnostički plan uključio je kompletan oftalmološki pregled, gonioskopiju, impresijsku citologiju i magnetsku rezonanciju (MR), te je potvrđena dijagnoza karcinoma pločastih stanica bez širenja u orbitu i ostala intraokularna tkiva. Pacijent je podvrgnut kirurškoj ekscizijskoj biopsiji lezije, uz krioterapiju konjunktivalnih rubova i skleralne baze lezije. Nakon kirurške terapije, proveli smo topičku terapiju 0,02 % (0,2 mg/ml) Mitomycinom C (MMC) tijekom 14 dana. Kontrolna ekscizijska biopsija ruba spojnice i strugotine zahvaćene rožnice provedena je posljednjeg dana topičke kemoterapije. Zbog pozitivnog nalaza tumorskih stanica u rožničnom tkivu nastavljena je topička kemoterapija 0,04 % (0,4 mg/ml) MMC-om tijekom sljedeća 3 tjedna. Pacijent je redovito praćen tijekom posljednjih 20 mjeseci bez recidiva bolesti. **Zaključci:** OSSN je kirurški izazov jer zahtijeva specijaliziranu *no-touch* operativnu tehniku. U našem slučaju, kombinacija kirurškog zahvata s intraoperativnom krioterapijom, te nakon toga topička kemoterapija 0,02 % kapima Mitomycinom tijekom 14 dana, uz nastavljen drugi ciklus topičke kemoterapije 0,04 % kapima Mitomycinom tijekom sljedećeg razdoblja od 21 dana zbog pozitivne kontrolne biopsije dobar je izbor za liječenje OSSN-a uz pažljivo daljnje praćenje pacijenta.

Ključne riječi: konjunktiva; mitomycin; neoplazme oka; rožnica; skvamocelularne neoplazme

***Corresponding author:**

Marijana Bilen Babić, MD
Department of Ophthalmology,
Clinical Hospital Center Rijeka
Krešimirova 42, 51 000 Rijeka, Croatia
e-mail: marijanaabb@gmail.com

<http://hrcak.srce.hr/medicina>

INTRODUCTION

Ocular surface squamous neoplasia (OSSN) is a term that encompasses a wide and varied spectrum of very rare dysplastic diseases of the cornea and conjunctiva with a figure ranging from conjunctival intraepithelial neoplasia (CIN), carcinoma in situ (CIS) to invasive squamous cell carcinoma (SCC) of conjunctiva and/or cornea. In 1995, Lee and Hirst first proposed the term OSSN and defined it as intraepithelial and invasive squamous cell carcinoma of the conjunctiva and cornea¹. The incidence of OSSN ranges from 0,02-3,5 per 100,000 and it is well recognized that the prevalence of OSSN is increased near the equator area². Risk factors include advanced age², light skin pigmentation³, UVB light exposure⁴, tobacco smoke⁵, exposure to petroleum products^{3,4}, HPV infection with types 16 and 18⁶. Infection with human immunodeficiency virus (HIV) has been associated with higher incidence of OSSN (4-7,8 %)⁷. OSSN is usually a slowly growing tumor and rarely spreads to corneal stroma, sclera, deeper intraocular or orbital structures². It rarely metastasizes to the preauricular, submandibular and upper deep cervical lymph nodes², but systemic metastases are rare. Intraocular invasion has been reported in 2 %-15 %⁸ and orbital invasion in 12-16 %⁹. In rare cases, it may lead to systemic spread disorders.

Generally, OSSN is presented as a chronic irritation, a gelatinous opalescent papillary mass appearing at limbus, in interpalpebral fissure area, with feeder vessels supplying the masses and it can mimic degenerative alterations as pterygium, pinguecula or papilloma.

Clinically, the lesions are difficult to differentiate since OSSN includes benign ocular surface changes such as squamous papillomas, precancer as actinic keratosis and conjunctival intraepithelial neoplasia (CIN), carcinoma-in-situ (CIS) and squamous cell carcinoma (SCC)². In histopathological terms, conjunctival intraepithelial neoplasia (CIN) is characterized by a replacement of the conjunctival epithelium with atypical squamous cells. In carcinoma-in-situ (CIS) there is a full thickness replacement of epithelium by malignant cells, but with no invasion revealed to the substantia propria, as opposite to invasive squamous cell

carcinoma (SCC) where malignant cells invade the substantia propria.

Diagnostic procedure of OSSN includes biomicroscopy, gonioscopy (for the assessment of intraocular angle involvement), ultrasound biomicroscopy (for the assessment of scleral and intraocular involvement), impression cytology (IC) and tissue histology, computerised tomography (CT) scans and magnetic resonance (MR) scans to determine intraocular, intraorbital or intracranial expansion.

Ocular surface squamous neoplasia (OSSN) is a term that encompasses a wide and varied spectrum of very rare dysplastic diseases of the cornea and conjunctiva with a picture ranging from conjunctival intraepithelial neoplasia (CIN), carcinoma in situ (CIS) to invasive squamous cell carcinoma (SCC) of conjunctiva and/or cornea.

The goals in managing ocular surface squamous neoplasia are to excise the tumor with clear tissue margins and to remove any remaining tumor cells involved. The established method of treatment for OSSN is complete surgical excisional biopsy with resection of a 3-4 mm tumor-free conjunctival tissue margin and thin scleral flap below the tumor.

Affected cornea is treated with application of 100 % alcohol and removal of involved epithelium to 2 mm from the edges of the tumor and deep down to Bowman membrane. Supplemental cryotherapy to cut conjunctival edges and scleral base is applied. Shields popularized the 'no-touch' technique while keeping operative 'dry field' without washing with Balanced Salt Solution (BSS), to prevent the dispersion of malignant cells¹⁰.

Topical chemotherapy can be used as adjunctive therapy to surgery or primary therapy. It includes Mitomycin C (MMC) as the most common application, 5-fluorouracil (5-FU) and interferon alpha-2b, as less toxic compared to the previous one. Brachytherapy or internal radiation therapy are rarely used in cases of extensive or neglected lesions with unclear borders or as a palliative therapy¹¹.

CASE REPORT

In March 2013, a 78-year old man presented at our ophthalmologic emergency ward with symptoms including redness, tearing and itching of the left eye persisting for last 8 months, with a gradual decline of vision and visible swelling on his eye surface. His ocular and medical histories were unremarkable.

Ocular surface squamous neoplasia is a surgical challenge requiring a specialized 'no-touch'(NT) technique of surgery. It is important that the surgeon use a minimal manipulation technique for tumor resection to avoid the transfer and implantation of tumor cells into previously uninvolved areas.




Figure 1 Clinical appearance of patient with squamous cell carcinoma of cornea and conjunctiva




Figure 2 Immunohistochemical stains exhibiting squamous cell carcinoma (Hematoxylin and eosin stain)

Patient's uncorrected visual acuity was 0.4 according to Snellen chart. Slit lamp examination showed diffuse elevated conjunctival papilloma lesion with expansion to the limbus and adjacent corneal epithelium with residential feeder vessel supplying the masses (Figure 1). Gonioscopy was performed to assess the degree of angle involvement and it showed unaffected angle in II visible part circumference of IV. Impression cytology (IC) demonstrated the presence of lesion-related malignant cells of squamous epithelium (Figure 2). Photodocumentation of ocular surface alterations were presented. Magnetic resonance imaging (MRI) scans with Gadolinium enhancement using 2 mm cuts showed noorbital or deeper intraocular tissue spreads. Clinical examination of preauricular, submandibular and upper deep cervical lymph nodes excluded the occurrence of invasion. Patient was also presented to the oncologist.

Our therapeutic management consisted of surgical excisional biopsy of conjunctival lesion with resection of 3-4 mm tumor-free conjunctival tissue margin and cryotherapy of cut conjunctival edge and base of the lesion. The cornea involved was removed with application of 100 % absolute alcohol. On the first postoperative day, topical chemotherapy started with 0.2 mg/ml (0.02 %) of Mitomycin C (MMC) with daily 2 minutes' applications for next 14 days. Control excisional biopsy of conjunctival edge and abrasion of the affected cornea were performed following the last day of MMC topical chemotherapy application. Three days after the control excisional biopsy, amniotic membrane transplantation was performed for ocular surface reconstruction. The control excisional conjunctival-corneal biopsy revealed tumor-cells negative conjunctival tissue and tumor – cells positive corneal tissue.

Due to the positive control excisional biopsy, we started the second cycle of topical chemotherapy with 0.4 mg/ml (0.04 %) MMC drops administered 4 times daily for the next 3 weeks.

One month following the last day of therapy the slit lamp examination showed complete clinical resolution of the lesion with only macula on the cornea previously surgically treated (Figure 3). The patient has now been followed-up for 20

months with 1-month, 4-months and 6-months' visits respectively, with no recurrence of the disease. Patient's current visual acuity is 0.4 according to Snellen chart. There were no recorded complications due to MMC application. Patient shall be carefully monitored for the following period.

DISCUSSION AND CONCLUSION

Ocular surface squamous neoplasia (OSSN) is a very rare tumor which occurs in sun damaged ocular surface, usually at the limbus in elderly men¹¹. The most common method of treatment for conjunctival neoplasms has been wide local excision with supplemental cryotherapy to the surgical margins and primary or adjuvant chemotherapy. Topical chemotherapies can be used as nonsurgical method for treating the entire conjunctival surface in case of multicentric or ill-defined lesions, with minimal side effects and possibility of repeating the therapy cycles depending on clinical response¹¹.

Topical Mitomycin C has been used as most common topical chemotherapeutic treatment option that delivers high drug concentrations and can help in treating diffuse, multicentric and deep lesions¹²⁻¹³. It can be used pre-operatively as chemoreduction agent¹⁴ or post-operatively to minimize the possibility of recurrence of disease¹⁵. An incomplete excision with positive surgical margins has been identified as a major risk factor for recurrence. Recurrence of OSSN after surgical treatment is common with 33 % of patients with negative conjunctival margins and 56 % with positive margins over a 10-year period, as published in the study with the longest follow-up¹⁶.

Ocular surface squamous neoplasia is a surgical challenge requiring a specialized 'no-touch' (NT) technique of surgery¹⁰. It is important that the surgeon use a minimal manipulation technique for tumor resection to avoid the transfer and implantation of tumor cells into previously uninvolved areas.

In our case, the combination of surgical excision with intraoperative cryotherapy and topical chemotherapy with 0.02 % MMC application for 14 days, completed with second cycle of topical



Figure 3 Clinical appearance of patient at 10-month follow up visit after treatment

0.04 % MMC drops for the next 21 days given the positive control biopsy, proved to be a good choice for eradication of OSSN with accurate further monitoring of the patient.

Conflicts of interest statement: The authors report no conflicts of interest.

REFERENCES

1. Lee GA, Hirst LW. Ocular surface squamous neoplasia. *Surv Ophthalmol* 1995;39:429-50.
2. Othman IS. Ocular surface tumors. *Oman J Ophthalmol* 2009;2:3-14.
3. Kiire CA, Dhillon B. The aetiology and associations of conjunctival intraepithelial neoplasia. *Br J Ophthalmol* 2006;90:109-13.
4. Lee GA, Williams G, Hirst LW, Green AC. Risk factors in the development of ocular surface epithelial dysplasia. *Ophthalmology* 1994;101:360-4.
5. McDonnell JM, Mayr AJ, Martin WJ. DNA of human papillomavirus type 16 in dysplastic and malignant lesions of the conjunctiva and cornea. *N Engl J Med* 1989;320:1442-6.
6. Scott IU, Karp CL, Nuovo GJ. Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia. *Ophthalmology* 2002;109:542-7.
7. Karp CL, Scott IU, Chang TS, Pflugfelder SC. Conjunctival intraepithelial neoplasia: A possible marker for human immunodeficiency virus infection? *Arch Ophthalmol* 1996;114:257-61.
8. Tunc M, Char DH, Crawford B, Miller T. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: Analysis of 60 cases. *Br J Ophthalmol* 1999;83:98-103.
9. Erie JC, Campbell RJ, Liesegang TJ. Conjunctival and corneal intraepithelial and invasive neoplasia. *Ophthalmology* 1986;93:176-83.
10. Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors: The 1994 Lynn B McMahhan Lecture. *Arch Ophthalmol* 1997;115:808-15.

11. Kim JW, Abramson DH. Topical treatment options for conjunctival neoplasms. *Clin Ophthalmol* 2008;2: 503–15.
12. Frucht-Pery J, Sugar J, Baum J, Sutphin JE, Pe'er J, Savir H et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: A multicenter experience. *Ophthalmology* 1997;104:2085–93.
13. Wilson MW, Hungerford JL, George SM, Madreperla SA. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. *Am J Ophthalmol* 1997;124:303–11.
14. Shields CL, Demirci H, Marr BP, Masheyekhi A, Materin M, Shields JA. Chemoreduction with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva. *Arch Ophthalmol* 2005;123:109–13.
15. Chen C, Louis D, Dodd T, Muecke J. Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia. *Br J Ophthalmol* 2004;88:17–8.
16. Tabin G, Levin S, Snibson G, Loughnan M, Taylor H. Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. *Ophthalmology* 1997;104:485–92.